Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Uterine Cervical Neoplasms

Carcinoma

Pancreatic Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Pancreatic Cancer

* Patients will have blood and tumor collected at various time points throughout participation in the study.
* Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI.

Cliff Robinson, M.D.

Carl DeSelm, M.D., Ph.D.

Stephanie Markovina, M.D., Ph.D.

Julie Schwarz, M.D., Ph.D.

Jessika Contreras, M.D.

Dineo Khabele, M.D.

David DeNardo, Ph.D.

Hyun Kim, M.D.

Kian-Huat Lim, M.D.

Ryan Fields, M.D.

Jeff Szymanski, M.D.

Hua Li, Ph.D.

Albert Lai, Ph.D.

Philip Payne, Ph.D.

Doug Caruthers, M.S.

Esther Lu, Ph.D.

Lei Liu, Ph.D.

Andrea Hagemann, M.D.

Lindsay Kuroki, M.D.

Leslie Stuart Massad, M.D.

Carolyn McCourt, M.D.

Maggie Mullen, M.D.

Matthew Powell, M.D.

Brooke Sanders, M.D.

Premal Thaker, M.D.

This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment (imaging, dosimetry, clinical) data before, during, and after treatment with definitive-intent standard of care (SOC) radiotherapy for patients with locally advanced cervical and pancreatic cancer.

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial (METEOR-CRATR)

Data will be presented at scientific meetings \& published in journals. Individual-level \& aggregate genomic data will be deposited/made available through GEO \& SRA. Includes sequence, transcriptomic, epigenomic, \& gene expression data. Raw mass spectra \& unprocessed proteomic data will be shared through publisher mechanisms. Will use PRIDE \& ProteomeEXchange to share protein identifications \& spectral evidence. METEOR-BLST will collaborate with ROBIN centers to share expertise, data reporting and discovering of radiation biology. Data generated in this proposal will be shared with the scientific community subject to NIH \& institutional regulations. BLST will manage \& assist in dissemination of omics data generated. NIMS data will be deposited at MetaboLights. CODEX-based imaging data will be as supplemental files within manuscripts. Processed data will be available through CIELO. Model organisms generated will be distributed freely, or deposited into a repository/stock center.

Generalized linear mixed effects models will be first used to capture the changes in the longitudinal values of a single assay output over time for a given biospecimen. Random effects will be used to describe the correlation of repeated measures on the same subject over time.

National Cancer Institute (NCI)

Washington University School of Medicine

Infections

Symptoms and General Pathology

Skin and Connective Tissue Diseases

Immune System Diseases

Blood and Lymph Conditions

Communicable Diseases

Skin Diseases

Autoimmune Diseases

Hematologic Diseases

Disease Attributes

Subjects for observational study Various conditions \& healthy subjects

Observational

iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively "research").

The level of involvement for each network institution will vary based on the type of specimen to which they have access (e.g. biofluids, tissues and/or cells) and the category of collection (remnant specimens that were originally collected for clinical testing and/or specimens specifically collected for research) in accordance with the institution's elected preferences.

In most cases, potential participants will be identified and approached upon presenting for clinical care or recruited specifically for the study using outreach programs. If additional screening activities are required to determine eligibility criteria, the potential participant may be presented with the opportunity to participate in these activities as part of the study. These screening activities will be minimal risk in nature and are described further below. Should potential participants meet screening criteria, they may then be asked to provide biospecimens according to current research needs. Individual participants or groups of participants may be sought according to specific clinical, lifestyle, and/or demographic characteristics. The providers of these samples may be healthy participants or participants with a medical condition of interest to the research community but regardless, all specimens collected under this protocol (whether for screening purposes and for distribution to researchers) will qualify as minimal risk activities.

Biospecimens may be distributed to researchers at academic institutions, hospitals, clinical and government laboratories, and corporations including diagnostic, medical device, biopharmaceutical and biotechnology companies. The types of research studies and testing that may be performed using the biospecimens will be varied, and it is not possible to provide a description of all potential studies. Some researchers may perform genetic testing on the specimens, some may use the specimens to develop cell lines, and some may cryopreserve the specimens for many years, awaiting a research use. The specimens may also be used for educational purposes, such as training lab techs on the proper testing of samples or physicians on the proper reading of stained slides. The iSpecimen consent forms will indicate a broad scope of possible research and educational uses and activities.

Collection and Distribution of Biospecimens for Novel Research

iSpecimen Network Protocol: Collection and Distribution of Remnant and Research Use Only Biospecimens for Novel Research

Repository of diseased and healthy tissue, blood derivatives and related biological specimens

Each subject will have contributed at least one biospecimen

iSpecimen Inc

Lymphoma

Lymphosarcoma

Dermatologic Agents

All Drugs and Chemicals

Coal Tar

Patients with cancer or benign tumors being treated on NCI/DTC studies

Jennifer H Zlott

Alice P Chen, M.D.

For more information at the NIH Clinical Center contact National Cancer Institute Referral Office

Background:

People who join a study in the Developmental Therapeutics Clinic (DTC) have tests. These include blood draws and biopsies. Researchers collect data from these samples. Some people take part in more than one study at the DTC. At this time, data are connected only with one single study. Researchers want to access people s medical records. This will allow them to link the research data from all their studies they have or will take part in. Researchers also want to collect medical data about their diagnosis and treatment history. This will allow them to see how their cancer reacted to different drugs over time.

Objective:

To enter people into a master protocol to connect research sample and treatment data across DTC studies.

Eligibility:

People ages 18 and older who are being evaluated or treated for cancer in the DTC

Design:

Participants will allow researchers to look at all the data from their research samples. This includes those from their current, past, and any future NIH studies.

Participants will allow researchers to access some of their medical data. This includes age, diagnosis, treatment history, and response to treatment.

Participants will provide no new samples.

...

Background:

Research samples and data collected on a treatment-intent protocol are discrete items associated with that protocol up until the patient comes off study, usually due to disease progression. These data are not stored in the patient s medical records, but are essential to understand tumor response to different drugs over time. Patients in the Developmental Therapeutics Clinic (DTC) often start other clinical trials; this protocol provides a mechanism to connect research data about that patient from one trial to the next as long as the patient remains eligible and has given his or her informed consent. No new analysis will be performed under this protocol.

There is research interest in collecting pre- and post-dose research biopsies and other samples such as circulating tumor cells to measure dynamic drug-specific target effects (e.g., changes in epithelial-mesenchymal transition, DNA damage response, or immunotherapeutic cell infiltration), and then to evaluate molecular changes before and during disease progression to understand why the tumors initially respond but then became resistant to treatment.

To accomplish this, we will connect research results from consecutive trials with limited patient information (age, gender, disease, prior therapies, protocol number/drug regimen, response, and duration of treatment).

Each patient who consents to participate in this non-treatment, longitudinal sample protocol agrees to allow his or her Medical Record Number (MRN) to be used to track participation on DTC clinical trials.

Objectives:

Patients will be entered onto this "master" longitudinal protocol to connect research sample and treatment data across consecutive DTC clinical trials.

Biopsy samples collected at time of disease progression on one research trial will be evaluated for use as the baseline sample for the next research trial, potentially obviating the need for additional biopsies.

Eligibility:

Adult patients who are being evaluated for and/or treated for cancer or benign tumors at the DTC.

Design:

No samples will be collected under this longitudinal protocol, no treatment decisions will be made based on data collected, and no new analysis will be performed.

Specimens for research purposes, as outlined in this protocol, will be those obtained from tests and procedures that are done as required by the primary research protocols that a given patient is enrolled in. Tissue collected under DTC tissue procurement protocol 06-C-0213 will not be used or tracked.

Sample location and use will be managed in the Repository at the Frederick National Laboratory for Cancer Research using LabMatrix software.

Patients may remain on this longitudinal protocol for the duration of their consent.

Sample Collection and Tracking for the Developmental Therapeutics Clinic

Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute

Collation of research sample and treatment data from individual patients across their participation in consecutive DTC clinical trials

Urinary Bladder Neoplasms

Urologic Neoplasms

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Matthew I Milowsky, MD

The purpose of this prospective biospecimen collection study is to evaluate the feasibility of measuring circulating tumor DNA (ctDNA) in subjects with muscle-invasive bladder cancer (MIBC) treated with trimodality therapy consisting of a maximal transurethral resection of bladder tumor followed by radiation and concomitant chemotherapy.

Cancer cells have unique genes that determine the characteristics of tumors, such as how they will respond to different treatments. The tumor tissue will be used to determine the genes present in cancer cells. Tumor cells sometimes release fragments of DNA into the blood or urine (circulating tumor DNA or ctDNA) and measuring levels of ctDNA may be a way to monitor cancer and predict to determine which treatment works better and what will be the outcome of cancer.

Urine, blood, and tumor tissue are called biospecimens. Biospecimens can help researchers understand how the human body works. Researchers may develop new tests to monitor diseases or new ways to treat diseases. Plasma and urine specimens will be collected before, during, and after the standard-of-care treatment.

This study will estimate the feasibility of collecting plasma ctDNA detection in subjects with MIBC. If this information can be successfully collected and processed, the usefulness of ctDNA to predict tumor response to certain kinds of treatment or disease progression will be evaluated.

ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy

Pilot Study to Evaluate the Role for Circulating Tumor DNA (ctDNA) in Monitoring Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy

There is no plan to share IPD with other researchers.

The feasibility of cell-free plasma ctDNA collection will be estimated by the percentage of specimens that yield a ctDNA result.

The feasibility of urine ctDNA collection will be estimated by the percentage of specimens that hat yield a ctDNA result.

UNC Lineberger Comprehensive Cancer Center

Heart and Blood Diseases

Syndrome

Preleukemia

Myelodysplastic Syndromes

Multiple Myeloma

Neoplasms, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Bone Marrow Diseases

Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.

Biopsy

Nancy Moore, R.N.

James H Doroshow, M.D.

Kathryn S Sutton, MD

Anna Maria Storniolo, MD

Stephanie Chen, MD

Nyall London, M.D. PHD

For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Ryan C. Fields, MD

John Kane, MD

Jim Rocco, MD, PhD

Kyle VanKoevering, MD

Rakesh Sindhi, MD

Kelly Smith, MD PhD

Background:

-Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.

Objectives:

* To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.
* To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.

Eligibility:

-Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center participating sites.

Design:

* This is a multicenter tissue procurement protocol with NCI as the coordinating center.
* For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocols to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol. Tissues and biological fluids to be procured may include but are not limited to blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.
* For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.
* Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture.
* This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate specimens for ongoing research on assay development and studies of molecular pathways, and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate specimens to create preclinical models.
* Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.

Background:

Patients who are being evaluated and/or treated at the NIH Clinical Center and at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens.

Objectives:

To obtain samples from adult and pediatric patients for research purposes from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment.

To obtain samples for research purposes from non-surgical procedures, such as percutaneous biopsies, performed for the sole purpose of obtaining tissue specimens or biological fluids for this protocol.

Eligibility:

Adult patients (18 years of age and older) and pediatric patients (younger than 18 years of age) who are being evaluated for and/or treated for cancer at the NIH Clinical Center and at participating sites.

Design:

This is a multicenter tissue procurement protocol with NCI as the coordinating center.

For adult patients: specimens for research purposes, as outlined in this protocol, will be obtained from tests and procedures that are done as required by the primary research protocol(s) to which a patient is enrolled or as part of their standard-of-care treatment. Non-surgical procedures, such as percutaneous biopsies, may also be performed on adult patients at the NIH Clinical Center for the sole purpose of obtaining tissue specimens or biological fluids. Tissues and biological fluids to be procured may include blood, serum, urine, tumor tissue, normal tissue, pleural fluid, CSF, saliva, bronchial alveolar lavage (BAL), circulating tumor cells, hair follicles, and bone marrow. These specimens will be stored with unique identifiers and used to perform only those research studies that are outlined in this protocol.

For pediatric patients: tumor biopsy/resection tissue used for pediatric preclinical model development will only be from tissue already being obtained as part of a procedure necessary for the patient s clinical care or as part of a primary research protocol; blood specimens will be collected as part of a blood collection already scheduled for the patient s clinical care or as part of the planned pre-procedure bloodwork; volumes collected will not exceed institutional research limits.

Given the risks associated with any invasive procedure, such as tumor biopsy, the procedure will be discussed in detail with the patients and their parents/guardian (as indicated), including the side effects, prior to obtaining a separate consent for each procedure. A separate consent will not be signed prior to obtaining samples by minimally invasive measures, such as venipuncture.

This study has two separate consent forms at the NIH Clinical Center: one for adult patients to donate samples for ongoing research on assay development and studies of molecular pathways; and one for adult and age-appropriate pediatric patients to donate samples for the generation of preclinical models. The study also has consent form templates for adult and pediatric patients at participating sites to donate samples to create preclinical models.

Patients may remain on study for the duration of their consent or completion of the planned procedure, whichever comes first.

Collection of Tissue Samples for Cancer Research

Tissue Procurement Protocol for the Developmental Therapeutics Clinic, National Cancer Institute (NCI)

Delinking of patient samples for research

Respiratory Tract (Lung and Bronchial) Diseases

Lung Neoplasms

Breast Neoplasms

Empyema

Pleural Effusion, Malignant

Pleural Effusion

Respiratory Tract Neoplasms

Thoracic Neoplasms

Respiratory Tract Diseases

Pleural Diseases

Pleural Neoplasms

Suppuration

Inflammation

Any subject who has pleural fluid buildup from lung cancer, breast cancer, or lung infection

Carmmen Garcia

Luz Cuaboy

Jason Akulian, MD

Jason Akulian

Research with biospecimens such as blood, tissue, or body fluids can help researchers understand how the human body works. Researchers can make new tests to find diseases, understand how treatments work, or find new ways to treat a disease. The purpose of this study is to collect biospecimens for research from patients with known or suspected lung cancer. The information learned from the biospecimens may be used in future treatments. The purpose of this protocol is to create a pleural fluid registry for use in future studies.

UNC Pleural Fluid Registry

University of North Carolina Pleural Fluid Registry

Biological specimens and corresponding clinical data from subjects will be collected during standard of care procedures and medical record abstraction to support the creation of a pleural fluid registry.

Carcinoma, Merkel Cell

Polyomavirus Infections

Virus Diseases

DNA Virus Infections

Tumor Virus Infections

Carcinoma, Neuroendocrine

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Adenocarcinoma

Neoplasms, Nerve Tissue

Merkel Cell Carcinoma

Neuroendocrine Tumor

Neuroepithelioma

Subjects with a skin disease or at risk of developing a skin disease/ Family member of persons with a skin disease

Monica Taylor, R.N.

Heidi H Kong, M.D.

Background:

- Skin disease can have many causes. It can have widespread consequences, and in rare cases can lead to death. Researchers want to determine the causes of various types of skin diseases and find a way to treat them.

Objectives:

- To determine the causes of various skin diseases and find ways to treat them.

Eligibility:

* People ages 2 and older who have:

  * A skin disease or at risk of developing a skin disease OR
  * A family member of persons with a skin disease
* Healthy volunteers ages 2 and older

Design:

* Participants will be screened under a separate protocol.
* Participants may take a survey about how their skin condition affects their quality of life.
* Participants will have a medical history and a physical exam including a detailed skin exam. Pictures will be taken of their skin to document any skin disease.
* Participants will have specimens collected. This may include:

  * Several teaspoons of blood taken at each visit
  * Stool samples
  * Nail and body fluid (like saliva) samples
  * Cheek swabs. The inside of the cheek will be scraped for about a minute in each direction to collect cells.
  * Collection of skin samples with:

    * A swab (like a Q-tip)
    * Gently scraping skin to remove the outer layers of cells
    * Applying and removing 1-inch pieces of tape
* Participants may have up to 4 skin biopsies in 12 months, with 4 separate biopsies taken each time.

  * An area of skin will be numbed with an injection.
  * A piece of skin the size of a pencil eraser will be removed using a small instrument.
  * A flat scar usually develops at the biopsy site.

Background:

* Skin diseases represent one of the most common medical problems in the United States, affecting 1 in 3 people at any given time.
* Complex interactions between genetic background and the environment are relevant to understanding skin disease.
* By studying dermatoses, we may gain insight into the complex host-environment interactions that give rise to or exacerbate these skin conditions, and into links between inflammation and cancer.

Objective:

-To procure biologic samples for exploratory cellular, molecular, genetic and genomic biological studies from subjects with dermatologic conditions, subjects at risk for developing dermatologic conditions and healthy volunteers in the support of NIH biomedical studies

Eligibility:

-Subjects with or at risk of developing dermatologic diseases, family members of subjects with dermatologic diseases, or healthy volunteers, including adults and children.

Design:

* The purpose of this study is to examine, in an exploratory fashion, a variety of biologic assays relevant to the investigation of dermatologic diseases.
* Approximately 50 subjects are anticipated to consent to the study each year with an accrual ceiling of 500 consented subjects planned over 10 years.

Studies of Dermatologic Diseases Biospecimen Acquisition Protocol

Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Behaviors and Mental Disorders

Prostatic Neoplasms

Aggression

Prostatic Diseases

Genital Neoplasms, Male

Genital Diseases, Male

Participants will be asked to complete a baseline questionnaire that asks questions about their demographic information, medical history, and smoking habits when they first enroll in the study. They will also be asked to complete a follow-up questionnaire 2 years later. The questionnaires will each take about 25 minutes to complete.

Questionnaires

Participants will be asked to provide a saliva sample using the saliva kit that will be mailed to them. Detailed instructions for collection will be included in the saliva collection packet.

Saliva Samples

Participants will be asked for permission to obtain a sample of their tumor tissue. Participants will receive a medical release form. Once they complete it and mail it back, investigators will request a small amount of tissue collected during the participant's prostate biopsy (or during their surgery, if they had surgery) from their health care provider.

Tumor Tissue

Jong Park, Ph.D.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial	NCT05975593	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Cervical Cancer Pancreas Cancer Pancreatic Canc... Cancer of the C... Cancer of the P...		18 Years -	Washington University School of Medicine
Collection and Distribution of Biospecimens for Novel Research	NCT05080907	Cancer Healthy Gastrointestina... Autoimmune Dise... Infectious Dise... Women's Health:... Dermatologic Di... Blood Disease	Observational	1 Year - 99 Years	iSpecimen Inc
Sample Collection and Tracking for the Developmental Therapeutics Clinic	NCT03269578	Neoplasms Lymphoma		18 Years -	National Institutes of Health Clinical Center (CC)
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy	NCT05630131	Bladder Cancer Muscle-Invasive...		18 Years -	UNC Lineberger Comprehensive Cancer Center
Collection of Tissue Samples for Cancer Research	NCT00900198	Neoplasms Lymphomas Multiple Myelom... Myelodysplastic...	Biopsy	2 Months -	National Institutes of Health Clinical Center (CC)
MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial	NCT05975593	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Cervical Cancer Pancreas Cancer Pancreatic Canc... Cancer of the C... Cancer of the P...		18 Years -	Washington University School of Medicine
UNC Pleural Fluid Registry	NCT05620329	Lung Cancer Lung Infection Breast Cancer Malignant Pleur... Empyema		18 Years -	UNC Lineberger Comprehensive Cancer Center
UNC Pleural Fluid Registry	NCT05620329	Lung Cancer Lung Infection Breast Cancer Malignant Pleur... Empyema		18 Years -	UNC Lineberger Comprehensive Cancer Center
Studies of Dermatologic Diseases Biospecimen Acquisition Protocol	NCT02471352	Dermatologic Co... Healthy Volunte... Normal Voluntee... Carcinoma, Merk...		1 Day - 100 Years	National Institutes of Health Clinical Center (CC)
Biobank for African American Prostate Cancer Research in Florida	NCT03232411	Prostate Cancer	Questionnaires Saliva Samples Tumor Tissue	20 Years -	H. Lee Moffitt Cancer Center and Research Institute

Spots Global Cancer Trial Database for biospecimen

Every month we try and update this database with for biospecimen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for biospecimen

Every month we try and update this database with for biospecimen cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for biospecimen cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.